KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ginkgo Bioworks Holdings (DNA) FCF Margin (2020 - 2025)

Ginkgo Bioworks Holdings' FCF Margin history spans 6 years, with the latest figure at 142.78% for Q4 2025.

  • For Q4 2025, FCF Margin fell 1473.0% year-over-year to 142.78%; the TTM value through Dec 2025 reached 105.04%, up 6327.0%, while the annual FY2025 figure was 105.04%, 6327.0% up from the prior year.
  • FCF Margin reached 142.78% in Q4 2025 per DNA's latest filing, down from 81.38% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 13.75% in Q3 2021 to a low of 252.92% in Q1 2024.
  • Average FCF Margin over 5 years is 120.44%, with a median of 130.25% recorded in 2022.
  • Peak YoY movement for FCF Margin: skyrocketed 14495bps in 2022, then crashed -12239bps in 2023.
  • A 5-year view of FCF Margin shows it stood at 114.92% in 2021, then dropped by -15bps to 132.45% in 2022, then crashed by -33bps to 176.31% in 2023, then rose by 27bps to 128.05% in 2024, then decreased by -12bps to 142.78% in 2025.
  • Per Business Quant, the three most recent readings for DNA's FCF Margin are 142.78% (Q4 2025), 81.38% (Q3 2025), and 81.23% (Q2 2025).